Cagrilintide is a long-acting analogue of amylin, a naturally occurring peptide that is released in conjunction with insulin. Cagrilintide has shown promise in animal trials as a treatment for obesity and type 2 diabetes. It has been studied for benefits not just in type 2 diabetes, but for liver damage, alcohol-related liver disease, and heart/blood vessel disease. There is some speculation about the role of this peptide in Alzheimer’s disease as well, but no research has been published in that particular sub-domain, yet. Many trials, however, have looked at the combination of cagrilintide and semaglutide in the treatment of obesity and type 2 diabetes. The two proteins appear to work synergistically to provide more robust and more permanent weight loss effects. It is important to note that while preclinical studies suggest promising therapeutic potential, clinical trials in humans are limited. Further research needs to be done to determine the efficacy and safety profiles.
Sequence
Phe-Thr-Asn-Val-Ser-Cys-Thr-Thr-Ser-Lys-Glu
CAS Number
78989-999-999
Molecular Formula
C176H277N57O55S7
Molecular Weight
987.55
LL-37 Related research
What Is Cagrilintide?
Cagrilintide is a synthetic analogue of the naturally occurring protein amylin. It is designed to be resistant to degradation by proteases in the blood and thus has a longer half-life. Cagrilintide is not the first amylin analogue to be developed. That distinction belongs to pramlintide, which was developed in the early years of the 21st century. Pramlintide was established as an adjuvant to insulin treatment, allowing for the use of less insulin in controlling blood sugar. Essentially, it reduces the glucose spike that many diabetics face after eating and therefore leads to improved blood sugar control. The main factor that sets cagrilintide apart from pramlintide is its significantly longer half-life.
COA
HPLC
MS
- V. N. Anisimov, S. V. Mylnikov, and V. K. Khavinson, “Pineal peptide preparation epithalamin increases the lifespan of fruit flies, mice and rats,” Mech. Ageing Dev., vol. 103, no. 2, pp. 123–132, Jun. 1998. [PubMed]
- V. K. Khavinson, I. E. Bondarev, and A. A. Butyugov, “Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells,” Bull. Exp. Biol. Med., vol. 135, no. 6, pp. 590–592, Jun. 2003. [PubMed]
Reviews
There are no reviews yet.